medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2026-3-18-23medalphabet-4942Research ArticleСтатьиЦитокиновый профиль и предикторы эффективности генно-инженерной биологической терапии при псориазе и псориатическом артрите: обзор литературыCytokine profile and predictors of the efficacy of genetically engineered biological therapy for psoriasis and psoriatic arthritis: a literature reviewhttps://orcid.org/0009-0003-2378-6261РедькоС. Р.RedkoS. R.

Редько Софья Романовна, аспирант кафедры дерматовенерологии и косметологии

Москва

Redko Sofya R., postgraduate student at Dept of Dermatovenereology and Cosmetology

Moscow

sofyred@mail.ruhttps://orcid.org/0000-0001-9638-2290РудневаН. С.RudnevaN. S.

Руднева Наталья Сергеевна, к.м.н., главный врач, доцент кафедры пропедевтики внутренних болезней, курса дерматовенерологии2, главный внештатный специалист дерматовенеролог, косметолог Министерства здравоохранения Тульской области

Тула 

Rudneva Natalya S., PhD Med Sci, chief physician, associate professor at Dept of Propaedeutics of Internal Medicine, and the Dermatovenereology Course2, chief freelance specialist dermatovenerologist, cosmetologist at the Ministry of Health of the Tula Region

Tula 

natalya.rudneva@tularegion.ruФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской ФедерацииРоссияCentral State Medical Academy of the Administrative Department of the President of the Russian FederationRussian FederationГУЗ «Тульский областной клинический кожно-венерологический диспансер»РоссияTula Regional Clinical Dermatovenereological DispensaryRussian Federation20261404202603Дерматология (1)1823Copyright © Редько С.Р., Руднева Н.С., 20262026Редько С.Р., Руднева Н.С.Redko S.R., Rudneva N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4942

Псориаз и псориатический артрит (ПсА) рассматриваются как гетерогенные иммуновоспалительные заболевания с выраженным системным компонентом, формирование которых обусловлено сложным взаимодействием врожденного и адаптивного иммунитета. Центральную роль в патогенезе псориатической болезни играет ось IL-23/Th17/IL-17, однако все большее значение придается внеосевым медиаторам воспаления, включая IL-6, IL-8, IL-22, IL-33 и IL-35, отражающим тканевую специфичность и иммунную гетерогенность заболевания. Внедрение ингибиторов ФНО-α и IL-17A существенно улучшило кожные и суставные исходы, однако вариабельность клинического ответа и вторичная потеря эффективности остаются актуальной проблемой. Анализ данных клинических и иммунологических исследований свидетельствует о неоднородности динамики сывороточных цитокинов на фоне биологической терапии и необходимости поиска надежных предикторов ответа. Перспективным направлением является комплексная оценка цитокинового профиля и доступных гематологических маркеров системного воспаления, включая нейтрофильно-лимфоцитарное соотношение (NLR), как инструментов мониторинга и персонализации терапии.

Psoriasis and psoriatic arthritis (PsA) are recognized as heterogeneous immune-mediated inflammatory disorders with a pronounced systemic component, whose development is driven by complex interactions between innate and adaptive immunity. The IL-23/Th17/IL-17 axis plays a central role in the pathogenesis of psoriatic disease; however, increasing attention is being directed toward non-axis mediators, including IL-6, IL-8, IL-22, IL-33, and IL-35, which reflect tissue specificity and immunological heterogeneity. The introduction of TNF-α and IL-17A inhibitors has significantly improved both cutaneous and articular outcomes; nevertheless, variability in clinical response and secondary loss of efficacy remain substantial challenges. Evidence from clinical and immunological studies demonstrates heterogeneity in the dynamics of circulating cytokines during biologic therapy and underscores the need for reliable predictive biomarkers of treatment response. A comprehensive assessment of cytokine profiles, together with accessible hematological markers of systemic inflammation- particularly the neutrophil-to-lymphocyte ratio (NLR) – may represent a promising approach for disease monitoring and the advancement of personalized therapeutic strategies.

псориазпсориатический артритинтерлейкиныгенно-инженерная биологическая терапияпредикторы эффективностинейтрофильно-лейкоцитарное соотношениеpsoriasispsoriatic arthritisinterleukinsbiologic therapypredictors of treatment responseneutrophil-to-lymphocyte ratioReferencesКруглова Л.С., Бакулев А.Л., Коротаева Т.В. Псориаз. Москва: ГЭОТАР-Медиа; 2022. 320 с. ISBN978-5-9704-7105-0.Круглова Л.С., Бакулев А.Л., Коротаева Т.В. Псориаз. Москва: ГЭОТАР-Медиа; 2022. 320 с. ISBN978-5-9704-7105-0. Kruglova L.S., Bakulev A.L., Korotaeva T.V. Psoriasis. Moscow: GEOTAR-Media; 2022. 320 p. ISBN978-5-9704-7105-0. (In Russ.).Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369: m1590. https://doi.org/10.1136/bmj.m1590Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369: m1590. https://doi.org/10.1136/bmj.m1590Lembke S., Macfarlane G.J., Jones G.T. The worldwide prevalence of psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford).2024; 63 (12): 3211–3220. https://doi.org/10.1093/rheumatology/keae198Lembke S., Macfarlane G.J., Jones G.T. The worldwide prevalence of psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford).2024; 63 (12): 3211–3220. https://doi.org/10.1093/rheumatology/keae198Perez-Chada L.M., Elman S., Villa-Ruiz C., Armstrong A.W., Gottlieb A.B., Merola J.F. Psoriatic arthritis: A comprehensive review for the dermatologist. Part I: Epidemiology, comorbidities, pathogenesis, and diagnosis. J Am Acad Dermatol. 2025; 92 (5): 969–982. https://doi.org/10.1016/j.jaad.2024.03.058Perez-Chada L.M., Elman S., Villa-Ruiz C., Armstrong A.W., Gottlieb A.B., Merola J.F. Psoriatic arthritis: A comprehensive review for the dermatologist. Part I: Epidemiology, comorbidities, pathogenesis, and diagnosis. J Am Acad Dermatol. 2025; 92 (5): 969–982. https://doi.org/10.1016/j.jaad.2024.03.058Кубанов А.А., Богданова Е.В. и др. Эпидемиология псориаза в Российской Федерации по данным регистра пациентов. Вестник дерматологии и венерологии. 2022; (1): 33–41. https://doi.org/10.25208/vdv1268Кубанов А.А., Богданова Е.В. и др. Эпидемиология псориаза в Российской Федерации по данным регистра пациентов. Вестник дерматологии и венерологии. 2022; (1): 33–41. https://doi.org/10.25208/vdv1268 Kubanov A.A., Bogdanova E.V., et al. Epidemiology of psoriasis in the Russian Federation according to patient registry data. Bulletin of Dermatology and Venereology. 2022; (1): 33–41. (In Russ.). https://doi.org/10.25208/vdv1268Reich K., Kristensen L.E., Smith S.D., Rich P., Sapin C., Leage S.L. et al. Efficacy and safety of ixekizumab versus adalimumab in biologic-naïve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the SPIRIT-H2H trial. Dermatol Pract Concept. 2022; 12 (2): e2022104. https://doi.org/10.5826/dpc.1202a104Reich K., Kristensen L.E., Smith S.D., Rich P., Sapin C., Leage S.L. et al. Efficacy and safety of ixekizumab versus adalimumab in biologic-naïve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the SPIRIT-H2H trial. Dermatol Pract Concept. 2022; 12 (2): e2022104. https://doi.org/10.5826/dpc.1202a104Zhang A., Kurtzman D.J.B., Perez-Chada L.M., Merola J.F. Psoriatic arthritis and the dermatologist: an approach to screening and clinical evaluation. Clin Dermatol. 2018; 36 (4): 551–560. https://doi.org/10.1016/j.clindermatol.2018.04.011Zhang A., Kurtzman D.J.B., Perez-Chada L.M., Merola J.F. Psoriatic arthritis and the dermatologist: an approach to screening and clinical evaluation. Clin Dermatol. 2018; 36 (4): 551–560. https://doi.org/10.1016/j.clindermatol.2018.04.011Smolen J.S., Mease P., Tahir H. et al. Efficacy and safety of ixekizumab versus adalimumab in psoriatic arthritis: final results by week 52. Ann Rheum Dis. 2020;79(10):1310–1319. https://doi.org/10.1136/annrheumdis-2020–217372Smolen J.S., Mease P., Tahir H. et al. Efficacy and safety of ixekizumab versus adalimumab in psoriatic arthritis: final results by week 52. Ann Rheum Dis. 2020;79(10):1310–1319. https://doi.org/10.1136/annrheumdis-2020–217372Gossec L., Kerschbaumer A., Ferreira R.J.O., Aletaha D., Baraliakos X., Bertheussen H. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024; 83 (6): 706–719. https://doi.org/10.1136/ard-2024–225531Gossec L., Kerschbaumer A., Ferreira R.J.O., Aletaha D., Baraliakos X., Bertheussen H. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024; 83 (6): 706–719. https://doi.org/10.1136/ard-2024–225531Magee C., Jethwa H., FitzGerald O.M., Jadon D.R. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis. 2021; 13: 1759720X211014010. https://doi.org/10.1177/1759720X211014010Magee C., Jethwa H., FitzGerald O.M., Jadon D.R. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis. 2021; 13: 1759720X211014010. https://doi.org/10.1177/1759720X211014010Schwarz C.W., Loft N., Rasmussen M.K., Nissen C.V., Dam T.N., Egeberg A., Skov L. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol. 2021; 101 (10): adv00579. https://doi.org/10.2340/actadv.v101.351Schwarz C.W., Loft N., Rasmussen M.K., Nissen C.V., Dam T.N., Egeberg A., Skov L. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol. 2021; 101 (10): adv00579. https://doi.org/10.2340/actadv.v101.351Liu X.Q., Zhou P.L., Yin X.Y., Wang A.X., Wang D.H., Yang Y., Liu Q. Circulating inflammatory cytokines and psoriasis risk: a systematic review and meta-analysis. PLoS One. 2023; 18 (10): e0293327. https://doi.org/10.1371/journal.pone.0293327Liu X.Q., Zhou P.L., Yin X.Y., Wang A.X., Wang D.H., Yang Y., Liu Q. Circulating inflammatory cytokines and psoriasis risk: a systematic review and meta-analysis. PLoS One. 2023; 18 (10): e0293327. https://doi.org/10.1371/journal.pone.0293327Смирнова С.В., Смольникова М.В. Иммунопатогенез псориаза и псориатического артрита. Медицинская иммунология. 2014; 16 (2): 127–138. https://doi.org/10.15789/1563-0625-2014-2-127-138Смирнова С.В., Смольникова М.В. Иммунопатогенез псориаза и псориатического артрита. Медицинская иммунология. 2014; 16 (2): 127–138. https://doi.org/10.15789/1563-0625-2014-2-127-138 Smirnova S.V., Smolnikova M.V. Immunopathogenesis of psoriasis and psoriatic arthritis. Medical Immunology. 2014; 16 (2): 127–138. (In Russ.). https://doi.org/10.15789/1563-0625-2014-2-127-138Lowes M.A., Suárez-Fariñas M., Krueger J.G. Immunology of psoriasis. Annu Rev Immunol. 2014; 32: 227–255. https://doi.org/10.1146/annurev-immunol-032713–120225Lowes M.A., Suárez-Fariñas M., Krueger J.G. Immunology of psoriasis. Annu Rev Immunol. 2014; 32: 227–255. https://doi.org/10.1146/annurev-immunol-032713–120225Hawkes J.E., Chan T.C., Krueger J.G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017; 140 (3): 645–653. https://doi.org/10.1016/j.jaci.2017.07.004Hawkes J.E., Chan T.C., Krueger J.G. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017; 140 (3): 645–653. https://doi.org/10.1016/j.jaci.2017.07.004McInnes I.B., Mease P.J., Kirkham B. et al. Secukinumab in patients with psoriatic arthritis (FUTURE2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386 (9999): 1137–1146. https://doi.org/10.1016/S0140–6736(15)61134-5McInnes I.B., Mease P.J., Kirkham B. et al. Secukinumab in patients with psoriatic arthritis (FUTURE2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386 (9999): 1137–1146. https://doi.org/10.1016/S0140–6736(15)61134-5Moschetta M., Reale A., Marasco C., Vacca A., Carratù M.R. Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations. Br J Pharmacol. 2014;171(16):3801–3813. https://doi.org/10.1111/bph.12749Moschetta M., Reale A., Marasco C., Vacca A., Carratù M.R. Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations. Br J Pharmacol. 2014;171(16):3801–3813. https://doi.org/10.1111/bph.12749Boehncke W. H., Schön M. P. Psoriasis. Lancet. 2015; 386 (9997): 983–994. https://doi.org/10.1016/S0140–6736 (14) 61909-7Boehncke W. H., Schön M. P. Psoriasis. Lancet. 2015; 386 (9997): 983–994. https://doi.org/10.1016/S0140–6736 (14) 61909-7Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med. 2009; 361 (5): 496–509. https://doi.org/10.1056/NEJMra0804595Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med. 2009; 361 (5): 496–509. https://doi.org/10.1056/NEJMra0804595Chiricozzi A., Romanelli P., Volpe E., Borsellino G., Romanelli M. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018; 19 (1): 179. https://doi.org/10.3390/ijms19010179Chiricozzi A., Romanelli P., Volpe E., Borsellino G., Romanelli M. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018; 19 (1): 179. https://doi.org/10.3390/ijms19010179Veale D.J., Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018; 391 (10136): 2273–2284. https://doi.org/10.1016/S0140–6736 (18) 30830-4Veale D.J., Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018; 391 (10136): 2273–2284. https://doi.org/10.1016/S0140–6736 (18) 30830-4Sieminska I., Pieniawska M., Grzywa T.M. The immunology of psoriasis: current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024; 66 (2): 164–191. https://doi.org/10.1007/s12016-024-08991-7Sieminska I., Pieniawska M., Grzywa T.M. The immunology of psoriasis: current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024; 66 (2): 164–191. https://doi.org/10.1007/s12016-024-08991-7Corbett M., Ramessur R., Marshall D. et al. Biomarkers of systemic treatment response in people with psoriasis: a scoping review. Br J Dermatol. 2022; 187 (4): 494–506. https://doi.org/10.1111/bjd.21677Corbett M., Ramessur R., Marshall D. et al. Biomarkers of systemic treatment response in people with psoriasis: a scoping review. Br J Dermatol. 2022; 187 (4): 494–506. https://doi.org/10.1111/bjd.21677Wolk K., Witte E., Wallace E. et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes. Eur J Immunol. 2006; 36 (5): 1309–1323. https://doi.org/10.1002/eji.200535503Wolk K., Witte E., Wallace E. et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes. Eur J Immunol. 2006; 36 (5): 1309–1323. https://doi.org/10.1002/eji.200535503Lo Y.H., Wu C.S., Chen Y.T. et al. Serum IL-22 and IL-6 correlations with psoriasis severity and phototherapy response. J Dermatol Sci. 2010; 58 (3): 225–227. https://doi.org/10.1016/j.jdermsci.2010.03.018Lo Y.H., Wu C.S., Chen Y.T. et al. Serum IL-22 and IL-6 correlations with psoriasis severity and phototherapy response. J Dermatol Sci. 2010; 58 (3): 225–227. https://doi.org/10.1016/j.jdermsci.2010.03.018Olejniczak-Staruch I., Narbutt J., Skibińska M., Lesiak A. Interleukin-22 and –6 decrease under long-term biologic therapy in psoriasis. Adv Dermatol Allergol. 2020; 37 (5): 705–711. https://doi.org/10.5114/ada.2020.101469Olejniczak-Staruch I., Narbutt J., Skibińska M., Lesiak A. Interleukin-22 and –6 decrease under long-term biologic therapy in psoriasis. Adv Dermatol Allergol. 2020; 37 (5): 705–711. https://doi.org/10.5114/ada.2020.101469Arican O., Aral M., Sasmaz S., Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005; (5): 273–279. https://doi.org/10.1155/MI.2005.273Arican O., Aral M., Sasmaz S., Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005; (5): 273–279. https://doi.org/10.1155/MI.2005.273Bai F., Zheng W., Dong Y. et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2017; 9 (1): 1266–1278. https://doi.org/10.18632/oncotarget.22260Bai F., Zheng W., Dong Y. et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2017; 9 (1): 1266–1278. https://doi.org/10.18632/oncotarget.22260Паньшина Н. Н., Шилова Л. Н. Особенности цитокинового профиля у больных псориатическим артритом. Медицинский вестник Северного Кавказа. 2017; (4): 355–358. https://doi.org/10.14300/mnnc.2017.12099Паньшина Н. Н., Шилова Л. Н. Особенности цитокинового профиля у больных псориатическим артритом. Медицинский вестник Северного Кавказа. 2017; (4): 355–358. https://doi.org/10.14300/mnnc.2017.12099 Panshina N.N., Shilova L.N. Features of the cytokine profile in patients with psoriatic arthritis. Medical Bulletin of the North Caucasus. 2017; (4): 355–358. (In Russ.). https://doi.org/10.14300/mnnc.2017.12099Mitsui A., Tada Y., Takahashi T. et al. Serum IL-33 levels are increased in patients with psoriasis. Clin Exp Dermatol. 2016; 41 (2): 183–189. https://doi.org/10.1111/ced.12670Mitsui A., Tada Y., Takahashi T. et al. Serum IL-33 levels are increased in patients with psoriasis. Clin Exp Dermatol. 2016; 41 (2): 183–189. https://doi.org/10.1111/ced.12670Li T., Gu M., Liu P. et al. Clinical significance of decreased interleukin-35 expression in patients with psoriasis. Microbiol Immunol. 2018; 62 (6): 373–379. https://doi.org/10.1111/1348–0421.12605Li T., Gu M., Liu P. et al. Clinical significance of decreased interleukin-35 expression in patients with psoriasis. Microbiol Immunol. 2018; 62 (6): 373–379. https://doi.org/10.1111/1348–0421.12605Sakkas L.I., Mavropoulos A., Perricone C., Bogdanos D.P. IL-35: a new immunomodulator in autoimmune rheumatic diseases. Immunol Res. 2018; 66 (3): 305–312. https://doi.org/10.1007/s12026-018-8998-3Sakkas L.I., Mavropoulos A., Perricone C., Bogdanos D.P. IL-35: a new immunomodulator in autoimmune rheumatic diseases. Immunol Res. 2018; 66 (3): 305–312. https://doi.org/10.1007/s12026-018-8998-3Zaba L.C., Cardinale I., Gilleaudeau P. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–3194. https://doi.org/10.1084/jem.20071094Zaba L.C., Cardinale I., Gilleaudeau P. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–3194. https://doi.org/10.1084/jem.20071094Caproni M., Antiga E., Melani L. et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009; 29 (2): 210–214. https://doi.org/10.1007/s10875-008-9233-0Caproni M., Antiga E., Melani L. et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009; 29 (2): 210–214. https://doi.org/10.1007/s10875-008-9233-0Morita A., Tani Y., Matsumoto K. et al. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab. J Dermatol. 2020; 47 (5): 452–457. https://doi.org/10.1111/1346–8138.15278Morita A., Tani Y., Matsumoto K. et al. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab. J Dermatol. 2020; 47 (5): 452–457. https://doi.org/10.1111/1346–8138.15278Ziolkowska-Banasik D., Pastuszczak M., Zawadzinska-Halat K. et al. Serum IL-18/IL-13 ratio predicts super response to secukinumab in patients with psoriasis. Int J Mol Sci. 2025;26(13):6432. https://doi.org/10.3390/ijms26136432Ziolkowska-Banasik D., Pastuszczak M., Zawadzinska-Halat K. et al. Serum IL-18/IL-13 ratio predicts super response to secukinumab in patients with psoriasis. Int J Mol Sci. 2025;26(13):6432. https://doi.org/10.3390/ijms26136432Miyagawa I., Nakayamada S., Ueno M. et al. Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis. Arthritis Res Ther. 2022; 24 (1): 86. https://doi.org/10.1186/s13075-022-02771-4Miyagawa I., Nakayamada S., Ueno M. et al. Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis. Arthritis Res Ther. 2022; 24 (1): 86. https://doi.org/10.1186/s13075-022-02771-4Medjedovic L., Vižlin A., Andersch Björkman Y. et al. Impact of brodalumab on serum levels of IL-6, IL-17A, IFN-α, IFN-γ, and TNF-α in patients with psoriasis who failed treatment with TNF-α inhibitors. Int J Mol Sci. 2026; 27 (1): 458. https://doi.org/10.3390/ijms27010458Medjedovic L., Vižlin A., Andersch Björkman Y. et al. Impact of brodalumab on serum levels of IL-6, IL-17A, IFN-α, IFN-γ, and TNF-α in patients with psoriasis who failed treatment with TNF-α inhibitors. Int J Mol Sci. 2026; 27 (1): 458. https://doi.org/10.3390/ijms27010458Skougaard M., Søndergaard M.F., Ditlev S.B., Kristensen L.E. Changes in inflammatory cytokines in responders and non-responders to TNFα inhibitor and IL-17A inhibitor in psoriatic arthritis. Int J Mol Sci. 2024; 25 (5): 3002. https://doi.org/10.3390/ijms25053002Skougaard M., Søndergaard M.F., Ditlev S.B., Kristensen L.E. Changes in inflammatory cytokines in responders and non-responders to TNFα inhibitor and IL-17A inhibitor in psoriatic arthritis. Int J Mol Sci. 2024; 25 (5): 3002. https://doi.org/10.3390/ijms25053002Furue M., Tsuji G., Mitoma C. et al. Pathogenesis of psoriasis and the development of targeted therapies. J Dermatol Sci. 2018; 92 (3): 217–224. https://doi.org/10.1016/j.jdermsci.2018.08.025Furue M., Tsuji G., Mitoma C. et al. Pathogenesis of psoriasis and the development of targeted therapies. J Dermatol Sci. 2018; 92 (3): 217–224. https://doi.org/10.1016/j.jdermsci.2018.08.025Wang W.M., Wu C., Gao Y.M. et al. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients. BMC Immunol. 2021; 22: 64. https://doi.org/10.1186/s12865-021-00454-4Wang W.M., Wu C., Gao Y.M. et al. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients. BMC Immunol. 2021; 22: 64. https://doi.org/10.1186/s12865-021-00454-4Ataseven A., Bilgin A.U., Kurtipek G.S. The importance of neutrophil lymphocyte ratio in patients with psoriasis. Clin Med Res. 2014; 3 (2): 72–75. https://doi.org/10.11648/j.cmr.20140302.17Ataseven A., Bilgin A.U., Kurtipek G.S. The importance of neutrophil lymphocyte ratio in patients with psoriasis. Clin Med Res. 2014; 3 (2): 72–75. https://doi.org/10.11648/j.cmr.20140302.17Asahina A., Kubo N., Umezawa Y. et al. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: response to therapy with biologics. J Dermatol. 2017; 44 (10): 1112–1121. https://doi.org/10.1111/1346–8138.13875Asahina A., Kubo N., Umezawa Y. et al. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: response to therapy with biologics. J Dermatol. 2017; 44 (10): 1112–1121. https://doi.org/10.1111/1346–8138.13875

The authors declare that there are no conflicts of interest present.